Health IT, Startups

Digital startup focused on women’s and family health secures $27M

The company, Maven, raised funding from investors including Sequoia Capital, Oak HC/FT, 14W, Female Founders Fund and Spring Mountain Capital.

pregnant, woman, child, baby, pregancy

Maven, a startup focused on women’s and family health, has secured $27 million in a Series B funding round led by Sequoia Capital and Oak HC/FT. Existing investors 14W, Female Founders Fund and Spring Mountain Capital also participated.

Founded in 2014, the New York City company offers a virtual clinic that allows women to video chat or message with a variety of practitioners, including OB/GYNs, mental health specialists, pediatricians, nutritionists and more.

In addition to its tool for consumers, Maven has a family benefits platform for employers and health plans. Through it, the startup offers employees and members programs around fertility, maternity, adoption and returning to work. Maven clients like Bumble and Snap currently use it.

The new $27 million will go toward enhancing that family benefits platform.

“In a system that desperately needs reform, focusing on the core patient — women — and starting with the core experience of millennials starting families is critical,” Maven founder and CEO Kate Ryder said in a statement. “This is the beginning of a long-overdue change in our healthcare system and in society at large.”

In addition to the latest funding news, the New York City company said it has expanded its product offerings. Maven now has a breastmilk shipping service, which it hopes will provide mothers with support as they return to work.

Back in 2015, the startup scored $2.2 million in seed funding. Great Oaks Venture Capital, BoxGroup and F Cubed (Female Founders Fund) all participated, as did several angel investors such as Matt Mullenweg, Susan Lyne and Thomas Lehrman.

A startup focused on a different aspect of women’s health also announced a fundraising round recently. Based in Menlo Park, California, Alydia Health raked in a $10 million Series B round to conduct a clinical trial for its vacuum-based solution to postpartum hemorrhage.

Photo: shironosov, Getty Images

Shares0
Shares0